Stockscreener 앱 받기
14.17
3.20%
0.44
시간 외 거래:
14.09
-0.08
-0.56%
전일 마감가:
$13.73
열려 있는:
$13.69
하루 거래량:
7.13M
Relative Volume:
2.94
시가총액:
$1.85B
수익:
$745.97M
순이익/손실:
$-99.21M
주가수익비율:
-18.33
EPS:
-0.7729
순현금흐름:
$-5.09M
1주 성능:
+27.31%
1개월 성능:
+52.86%
6개월 성능:
+15.39%
1년 성능:
+97.91%
1일 변동 폭
$13.60
$14.23
1주일 범위
$10.96
$14.23
52주 변동 폭
$4.72
$14.23
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
14.17 | 1.79B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-29 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 개시 | Guggenheim | Neutral |
| 2025-04-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
Price to sales forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
NeoGenomics, Inc. Actuals & Estimates (BX:NG9) - TradingView
Price to book forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
NeoGenomics, Inc. Actuals & Estimates (SWB:NG9) - TradingView
Price to earnings forward of NeoGenomics, Inc. – LSX:120159 - TradingView
Carolyn Starrett joins NeoGenomics board of directors team - Gulfshore Business
Enterprise value to revenue forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
Enterprise value to EBITDA forward of NeoGenomics, Inc. – LSX:120159 - TradingView
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack - Yahoo Finance
NEO Forecast — Price Target — Prediction for 2027 - TradingView
Neogenomics stock hits 52-week high at 13.74 USD - Investing.com UK
Neogenomics stock hits 52-week high at 13.74 USD By Investing.com - Investing.com South Africa
NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants - Stock Titan
NeoGenomics (NEO) director Carolyn Starrett files initial Form 3 - Stock Titan
NeoGenomics, Inc. Announces Appointment of Carolyn Starrett to Board of Directors - marketscreener.com
NeoGenomics Taps AI Veteran for Board, Signaling Data-Driven Future - BriefGlance
NeoGenomics Appoints Carolyn Starrett to Board of Directors - citybiz
NeoGenomics appoints Carolyn Starrett to board of directors - Investing.com
NeoGenomics appoints Carolyn Starrett to board of directors By Investing.com - Investing.com Canada
NeoGenomics appoints Carolyn S. Starrett to its Board - TradingView
Carolyn Starrett joins NeoGenomics (NEO) board, expanding oncology and AI expertise - Stock Titan
Neogenomics Inc (NEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Does NeoGenomics' (NEO) 2032 Convertible Note Deal Reveal a New Oncology Diagnostics Playbook? - simplywall.st
Form 8K NeoGenomics Inc For: 22 June By Investing.com - Investing.com India
NeoGenomics, Inc. Announces $316 Million Offering of 0.75% Convertible Senior Notes Due 2032 and Indenture Agreement – Minichart - Minichart
NeoGenomics Prices $316.25M 0.75% Convertible Notes Due 2032; Adds Capped Calls, Repurchases Debt - TradingView
NeoGenomics (NASDAQ: NEO) sells $316M converts, refinances 2028 notes - Stock Titan
NeoGenomics Stock Rises as 2032 Convertible Notes Price at 35% Premium - timothysykes.com
NeoGenomics Stockanalyst consensus and long-term growth story - Ad-hoc-news.de
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Neogenomics Inc (NEO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neogenomics Inc (NEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neogenomics Inc (NEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neogenomics Inc (NEO) Institutional Confidence - TradingKey
Neogenomics Inc (NEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neogenomics Inc (NEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neogenomics Inc (NEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neogenomics Inc (NEO) Valuation: PE, PB & Fair Value Analysis - TradingKey
NeoGenomics (NASDAQ: NEO) director sells 5,307 shares in Form 4 - Stock Titan
NeoGenomics Prices $275 Million Convertible Senior Notes Offering to Repurchase Debt and Fund Growth - Minichart
NeoGenomics prices $275M convertible notes offering at 0.75% - Investing.com UK
NeoGenomics prices $275M convertible notes offering at 0.75% By Investing.com - Investing.com Australia
NeoGenomics Prices $275 Million Offering of Convertible Notes Due 2032 - marketscreener.com
NeoGenomics prices $275M convertible notes due 2032, plans repurchases of 2028 notes and shares - MSN
NeoGenomics (NASDAQ: NEO) refinances converts, plans $25M buyback - Stock Titan
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes - Business Wire
Is NeoGenomics Inc (NEO) a Bargain After 5.5% Drop? GF Value Says Undervalued - GuruFocus
(NEO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NeoGenomics Launches $275 Million Convertible Senior Notes Offering - Pulse 2.0
NeoGenomics launches $275M convertible notes offering due 2032 - MSN
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
0.62%
자본화:
|
볼륨(24시간):